1. Suppression of inflammatory and neuropathic pain by uncoupling CRMP-2 from the presynaptic Ca²⁺ channel complex.
- Author
-
Brittain JM, Duarte DB, Wilson SM, Zhu W, Ballard C, Johnson PL, Liu N, Xiong W, Ripsch MS, Wang Y, Fehrenbacher JC, Fitz SD, Khanna M, Park CK, Schmutzler BS, Cheon BM, Due MR, Brustovetsky T, Ashpole NM, Hudmon A, Meroueh SO, Hingtgen CM, Brustovetsky N, Ji RR, Hurley JH, Jin X, Shekhar A, Xu XM, Oxford GS, Vasko MR, White FA, and Khanna R
- Subjects
- Animals, Calcium Channels, N-Type metabolism, Calcium Channels, N-Type physiology, Dose-Response Relationship, Drug, Dura Mater drug effects, Dura Mater physiology, Maze Learning drug effects, Mice, Mice, Inbred C57BL, Motor Activity drug effects, Nerve Tissue Proteins drug effects, Pain metabolism, Pain physiopathology, Peptide Fragments drug effects, Posterior Horn Cells drug effects, Posterior Horn Cells physiology, Rats, Rats, Sprague-Dawley, Sensory Receptor Cells drug effects, Sensory Receptor Cells metabolism, Sensory Receptor Cells physiology, Synaptic Transmission drug effects, Synaptic Transmission physiology, Vasodilation drug effects, Calcium Channels, N-Type drug effects, Intercellular Signaling Peptides and Proteins physiology, Nerve Tissue Proteins physiology, Pain drug therapy, Peptide Fragments physiology
- Abstract
The use of N-type voltage-gated calcium channel (CaV2.2) blockers to treat pain is limited by many physiological side effects. Here we report that inflammatory and neuropathic hypersensitivity can be suppressed by inhibiting the binding of collapsin response mediator protein 2 (CRMP-2) to CaV2.2 and thereby reducing channel function. A peptide of CRMP-2 fused to the HIV transactivator of transcription (TAT) protein (TAT-CBD3) decreased neuropeptide release from sensory neurons and excitatory synaptic transmission in dorsal horn neurons, reduced meningeal blood flow, reduced nocifensive behavior induced by formalin injection or corneal capsaicin application and reversed neuropathic hypersensitivity produced by an antiretroviral drug. TAT-CBD3 was mildly anxiolytic without affecting memory retrieval, sensorimotor function or depression. At doses tenfold higher than that required to reduce hypersensitivity in vivo, TAT-CBD3 caused a transient episode of tail kinking and body contortion. By preventing CRMP-2-mediated enhancement of CaV2.2 function, TAT-CBD3 alleviated inflammatory and neuropathic hypersensitivity, an approach that may prove useful in managing chronic pain.
- Published
- 2011
- Full Text
- View/download PDF